Fentanyl inhibits the progression of human gastric carcinoma MGC-803 cells by modulating NF-κB-dependent gene expression in vivo

He,Guodong; Li,Li; Guan,Enjian; Chen,Jing; Qin,Yi; Xie,Yubo

doi:10.3892/ol.2016.4619

Fentanyl inhibits the progression of human gastric carcinoma MGC-803 cells by modulating NF-κB-dependent gene expression in vivo

Authors:
- Guodong He
- Li Li
- Enjian Guan
- Jing Chen
- Yi Qin
- Yubo Xie
View Affiliations

Affiliations: Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China, Department of Anesthesiology, The First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: May 25, 2016 https://doi.org/10.3892/ol.2016.4619
Pages: 563-571

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fentanyl is widely used to treat acute and chronic pain. Previous in vitro studies by the present authors demonstrated that fentanyl inhibits the progression of the MGC‑803 human gastric carcinoma cell line by affecting apoptosis‑related genes, including nuclear factor‑kappa B (NF‑κB) and phosphatase and tensin homolog. In the present study, the effects of fentanyl on NF‑κB‑dependent gene expression were investigated in vivo. Nude mice were inoculated with an MGC‑803 cell suspension, and mice that developed subcutaneous tumors measuring >1.0x1.0 cm were selected for study. Mice were administered intraperitoneal injections of fentanyl (0.05 mg/kg, group F1; 0.1 mg/kg, group F2; 0.2 mg/kg, group F3; and 0.4 mg/kg, group F4) for 14 consecutive days. Non‑fentanyl‑treated mice (group C) and normal saline‑treated mice (group N) served as the control groups. Tumor growth was monitored by calculating the time‑shift of the growth curve. Morphological changes were also observed using microscopy. The expression of NF‑κB, B‑cell lymphoma‑2 (Bcl‑2), B‑cell associated X protein (Bax), vascular endothelial growth factor‑A (VEGF‑A) and matrix metalloproteinase‑9 (MMP‑9) in the subcutaneous tumor tissue was also analyzed by reverse transcription‑polymerase chain reaction and western blot analysis, and confirmed using immunohistochemistry. The relative tumor volumes of groups F1, F2, F3 and F4 were significantly reduced compared with groups C and N. Furthermore, subcutaneous tumor cells exhibited nuclear swelling, chromatin condensation, reduced chromatin and nuclear fragmentation in the F1, F2, F3 and F4 groups. The number of NF‑κB+, Bcl‑2+, VEGF‑A+ and MMP‑9+ subcutaneous tumor cells was reduced, whereas the number of Bax+ cells was increased in the F1, F2, F3 and F4 groups. Additionally, in these groups, tumor expression of NF‑κB, Bcl‑2, VEGF‑A and MMP‑9 transcripts and proteins was downregulated, while Bax messenger RNA and protein expression levels were upregulated. The results revealed that fentanyl inhibits the growth of subcutaneous human gastric carcinoma tumors in mice. Therefore, it could be hypothesized that this antineoplastic activity may result from the inhibition of NF‑κB activation, suppression of downstream VEGF‑A and MMP‑9 expression, and normalization of the pro‑apoptotic Bax/Bcl-2 ratio.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Tsamandas AC, Kardamakis D, Tsiamalos P, Liava A, Tzelepi V, Vassiliou V, Petsas T, Vagenas K, Zolota V and Scopa CD: The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome. Anticancer Res. 29:703–709. 2009.PubMed/NCBI
3	Stanley TH: The fentanyl story. J Pain. 15:1215–1226. 2014. View Article : Google Scholar : PubMed/NCBI
4	Mystakidou K, Katsouda E, Parpa E, Vlahos L and Tsiatas ML: Oral transmucosal fentanyl citrate: Overview of pharmacological and clinical characteristics. Drug Deliv. 13:269–276. 2006. View Article : Google Scholar : PubMed/NCBI
5	Seifeldin R and Grossman P: Fentanyl transdermal system and oxycodone hydrochloride. J Manag Care Pharm. 9:457–459. 2003.PubMed/NCBI
6	Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007. View Article : Google Scholar : PubMed/NCBI
7	Qin Y, Li L, Chen J, Tang X, Liao C, Xie Y and Xiao Q: Fentanyl inhibits progression of human gastric cancer MGC-803 cells by NF-kappaB downregulation and PTEN upregulation in vitro. Oncol Res. 20:61–69. 2012. View Article : Google Scholar : PubMed/NCBI
8	Yang F, Wang H, Jiang Z, Hu A, Chu L, Sun Y and Han J: MicroRNA-19a mediates gastric carcinoma cell proliferation through the activation of nuclear factor-κB. Mol Med Rep. 12:5780–5786. 2015.PubMed/NCBI
9	Ma J, Liu J, Wang Z, Gu X, Fan Y, Zhang W, Xu L, Zhang J and Cai D: NF-kappaB-dependent microRNA-425 upregulation promotes gastric cancer cell growth by targeting PTEN upon IL-1β induction. Mol Cancer. 13:402014. View Article : Google Scholar : PubMed/NCBI
10	Beg AA, Sha WC, Bronson RT, Ghosh S and Baltimore D: Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. 376:167–170. 1995. View Article : Google Scholar : PubMed/NCBI
11	Baeuerle PA and Baltimore D: NF-kappa B: Ten years after. Cell. 87:13–20. 1996. View Article : Google Scholar : PubMed/NCBI
12	Yi J and Luo J: SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta. 1804:1684–1689. 2010. View Article : Google Scholar : PubMed/NCBI
13	Fabry ME, Kaul DK, Davis L, Gore JC, Brown M and Nagel RL: An animal model for sickle cell vaso-occlusion: A study using NMR and technetium imaging. Prog Clin Biol Res. 240:297–304. 1987.PubMed/NCBI
14	Fustéi Gamisans M and Busquet Duran X: Impact of the commercialization of transdermic fentanyl on the home care of terminal cancer patients. Aten Primaria. 29:316–317. 2002.(In Spanish). PubMed/NCBI
15	Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J and Singleton PA: The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and epithelial mesenchymal transition (EMT) in human lung cancer. PLoS One. 9:e915772014. View Article : Google Scholar : PubMed/NCBI
16	Zhang XL, Chen ML and Zhou SL: Fentanyl increases colorectal carcinoma cell apoptosis by inhibition of NF-κB in a Sirt1-dependent manner. Asian Pac J Cancer Prev. 15:10015–10020. 2014. View Article : Google Scholar : PubMed/NCBI
17	Kampa M, Bakogeorgou E, Hatzoglou A, Damianaki A, Martin PM and Castanas E: Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur J Pharmacol. 335:255–265. 1997. View Article : Google Scholar : PubMed/NCBI
18	Baldwin AS Jr: The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol. 14:649–683. 1996. View Article : Google Scholar : PubMed/NCBI
19	Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D and Miyamoto S: Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation. Genes Dev. 9:2723–2735. 1995. View Article : Google Scholar : PubMed/NCBI
20	Boland MP, Foster SJ and O'Neill LA: Daunorubicin activates NFkappaB and induces kappaB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells. J Biol Chem. 272:12952–12960. 1997. View Article : Google Scholar : PubMed/NCBI
21	Chang CK, Llanes S and Schumer W: Effect of dexamethasone on NF-κB activation, tumor necrosis factor formation, and glucose dyshomeostasis in septic rats. J Surg Res. 72:141–145. 1997. View Article : Google Scholar : PubMed/NCBI
22	Welters ID, Fimiani C, Bilfinger TV and Stefano GB: NF-kappaB, nitric oxide and opiate signaling. Med Hypotheses. 54:263–268. 2000. View Article : Google Scholar : PubMed/NCBI
23	Welters ID, Menzebach A, Goumon Y, Cadet P, Menges T, Hughes TK, Hempelmann G and Stefano GB: Morphine inhibits NF-kappaB nuclear binding in human neutrophils and monocytes by a nitric oxide-dependent mechanism. Anesthesiology. 92:1677–1684. 2000. View Article : Google Scholar : PubMed/NCBI
24	Scopa CD, Vagianos C, Kardamakis D, Kourelis TG, Kalofonos HP and Tsamandas AC: Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol. 9:329–334. 2001. View Article : Google Scholar : PubMed/NCBI
25	Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:609–619. 1993. View Article : Google Scholar : PubMed/NCBI
26	Crowson AN, Magro CM, Kadin ME and Stranc M: Differential expression of the bcl-2 oncogene in human basal cell carcinoma. Hum Pathol. 27:355–359. 1996. View Article : Google Scholar : PubMed/NCBI
27	Jeong SH, Lee HW, Han JH, Kang SY, Choi JH, Jung YM, Choi H, Oh YT, Park KJ, Hwang SC, et al: Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology. Jpn J Clin Oncol. 38:661–669. 2008. View Article : Google Scholar : PubMed/NCBI
28	Jin Z, Yan W, Jin H, Ge C and Xu Y: Differential effect of psoralidin in enhancing apoptosis of colon cancer cells via nuclear factor-kappaB and B-cell lymphoma-2/B-cell lymphoma-2-associated X protein signaling pathways. Oncol Lett. 11:267–272. 2016.PubMed/NCBI
29	Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J: Vascular-specific growth factors and blood vessel formation. Nature. 407:242–248. 2000. View Article : Google Scholar : PubMed/NCBI
30	Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
31	Spyridopoulos I, Luedemann C, Chen D, Kearney M, Chen D, Murohara T, Principe N, Isner JM and Losordo DW: Divergence of angiogenic and vascular permeability signaling by VEGF: Inhibition of protein kinase C suppresses VEGF-induced angiogenesis, but promotes VEGF-induced, NO-dependent vascular permeability. Arterioscler Thromb Vasc Biol. 22:901–906. 2002. View Article : Google Scholar : PubMed/NCBI
32	Takahashi S: Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 34:1785–1788. 2011. View Article : Google Scholar : PubMed/NCBI
33	Lee SJ, Kim JG, Sohn SK, Chae YS, Moon JH, Kim SN, Bae HI, Chung HY and Yu W: No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. Cancer Res Treat. 41:218–223. 2009. View Article : Google Scholar : PubMed/NCBI
34	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
35	Hansson J, Lind L, Hulthe J and Sundström J: Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: A population-based study. Eur J Cardiovasc Prev Rehabil. 16:297–303. 2009. View Article : Google Scholar : PubMed/NCBI
36	Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Bråkenhielm E and Cao Y: Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest. 117:2766–2777. 2007. View Article : Google Scholar : PubMed/NCBI
37	Cao R, Björndahl MA, Religa P, Clasper S, Garvin S, Galter D, Meister B, Ikomi F, Tritsaris K, Dissing S, et al: PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell. 6:333–345. 2004. View Article : Google Scholar : PubMed/NCBI
38	Sun WH, Sun YL, Fang RN, Shao Y, Xu HC, Xue QP, Ding GX and Cheng YL: Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. Jpn J Clin Oncol. 35:707–713. 2005. View Article : Google Scholar : PubMed/NCBI
39	Yang Q, Ye ZY, Zhang JX, Tao HQ, Li SG and Zhao ZS: Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anat Rec (Hoboken). 293:2012–2019. 2010. View Article : Google Scholar : PubMed/NCBI